Financial Performance - The company's operating revenue for Q1 2024 was CNY 3,242,814,513.73, a decrease of 4.99% compared to CNY 3,413,055,191.98 in the same period last year[6] - Net profit attributable to shareholders for Q1 2024 was CNY 607,823,809.46, representing an increase of 4.45% from CNY 581,909,331.89 year-on-year[6] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.65, up 4.84% from CNY 0.62 in the same quarter last year[6] - The company reported a gross profit margin of approximately 64.7%, compared to 63.1% in the previous period, indicating an improvement in profitability[38] - The total comprehensive income for the current period is RMB 693,127,170.79, an increase from RMB 547,848,808.47 in the previous period[39] Cash Flow - The net cash flow from operating activities surged by 208.30% to CNY 924,248,920.31, compared to CNY 299,784,593.85 in the previous year[6] - Cash flow from operating activities increased by 208.30% to RMB 924.25 million, attributed to reduced procurement and expense outflows[22] - Operating cash flow for the current period is RMB 924,248,920.31, a significant increase from RMB 299,784,593.85 in the previous period, reflecting a growth of approximately 208.5%[41] - Total cash inflow from operating activities is RMB 3,508,763,815.99, compared to RMB 3,446,124,787.42 in the prior period, indicating a slight increase of about 1.8%[41] - The net increase in cash and cash equivalents for the current period is -RMB 188,391,565.87, compared to an increase of RMB 527,826,015.13 in the previous period[43] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 25,189,695,757.11, reflecting a slight increase of 0.58% from CNY 25,044,827,127.75 at the end of the previous year[8] - The total liabilities decreased to RMB 9,750,195,000.46 from RMB 10,278,124,131.71, reflecting a reduction of approximately 5.12%[37] - The company's total equity increased to RMB 15,439,500,756.65 from RMB 14,766,702,996.04, representing a growth of about 4.54%[37] - The company's cash and cash equivalents stood at RMB 11,143,148,609.60, down from RMB 11,325,723,855.76 at the beginning of the year[35] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,751, with 43,538 being A-share shareholders[25] - The largest shareholder, Hong Kong Central Clearing Limited, holds 33.41% of shares, totaling 309,547,589 shares[25] - The company has initiated a share buyback program, resulting in treasury shares amounting to CNY 128,431,667.85[17] - The company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total share capital, with a total expenditure of RMB 73,436,534.00[30] - The company also repurchased 2,476,300 H-shares, representing 0.27% of the total share capital, with a total expenditure of HKD 60,363,260.00[31] Investment and Income - Investment income decreased by 58.41% to RMB 15.72 million, primarily due to last year's dividend income[22] - The company reported a 238.80% increase in minority shareholders' profit to RMB 108.26 million, driven by improved performance of non-wholly owned subsidiaries[22] - Other comprehensive income improved by 65.23%, primarily due to changes in the fair value of other equity instruments and foreign exchange fluctuations[22] Research and Development - Research and development expenses for the current period were RMB 238,173,559.46, down 23.5% from RMB 311,408,248.52 in the previous period[38] Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 17,522,920.17, primarily driven by government subsidies and asset disposals[13] - Other receivables increased by 43.55% to CNY 45,948,492.93, mainly due to an increase in export tax refunds[17] - The company reported a significant increase of 203.07% in other current assets, totaling CNY 156,230,044.47, attributed to new cash management operations[17] - The company's short-term borrowings decreased to RMB 1,360,009,625.00 from RMB 1,860,009,625.00, a reduction of 27%[37] - The deferred income tax liabilities decreased to RMB 202,497,603.77 from RMB 209,812,292.82, a decline of about 3.5%[37] Audit Status - The company has not undergone an audit for the first quarter report[45]
丽珠医药(01513) - 2024 Q1 - 季度业绩